Iradimed CORP: directors' dealings · United States · SEC (Form 4)

About Iradimed CORP

IRADIMED CORP. (ticker: IRMD) is a U.S.-based medical device company listed on the NASDAQ market in the United States. The company operates in a highly specialized segment of healthcare equipment: it designs, manufactures, markets, and distributes MRI-compatible medical devices, along with related accessories, disposables, and services. Its business is focused on safety-critical applications in hospitals and care settings where patients must receive infusion therapy and vital-sign monitoring during MRI procedures, an environment in which conventional equipment can pose safety and operational challenges. ([static1.squarespace.com](https://static1.squarespace.com/static/640779294f16ad6e3bf57fc8/t/6781a843facb34455f60e189/1736550467421/IRMD%2BPR%2B-%2BPreliminary%2BQ4%2B2024%2BRevenue%2Bfor%2BJPM%2B%28KLG%2BComments%29-508881756-v2.pdf)) IRADIMED’s roots go back to 1992, when it was originally incorporated in Oklahoma as IRI Development, Inc. The company was later reorganized into a Delaware corporation in April 2014. Its founder, Roger Susi, has a long operating history in MRI patient monitoring; he founded Invivo Research in 1979, where he helped develop the first MRI-compatible patient monitoring system. That historical lineage is important because it shows IRADIMED as a technology company built around decades of domain expertise in MRI-safe patient care. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm)) The product portfolio is centered on four core offerings for the scanner room: the MRidium 3870 MRI-compatible IV infusion pump system, the MRidium 3860+ MRI-compatible IV infusion pump system, the 3880 MRI-compatible patient vital signs monitoring system, and the 3600 FMD with RALU FMD. The company emphasizes that its pumps are non-magnetic, engineered for use in magnetic fields ranging from 0.2T to 3T, and equipped with clinical features such as drug libraries, alarms, and rechargeable battery operation. Management also states that IRADIMED has no current direct competitor in MRI-compatible IV infusion pumps, supporting a defensible niche position. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm)) Commercially, the company sells through a direct U.S. sales force and a network of international distributors. While its legacy market has been MRI departments, IRADIMED is expanding its footprint into intensive care units, emergency rooms, and other critical-care settings to broaden adoption of MRI-compatible devices across the hospital. The company’s headquarters and primary manufacturing operation are now located in Orlando, Florida, in a purpose-built facility of approximately 62,300 square feet that was funded entirely with cash. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm)) Recent developments have been constructive. In 2025, IRADIMED introduced the next-generation MRidium 3870 pump, which management says should support growth in 2026 and beyond. The company also increased shareholder returns, raising its regular quarterly dividend to $0.20 per share in February 2026 after declaring a special cash dividend of $0.50 per share in December 2025. In its 2026 outlook, management guided to revenue of $91 million to $96 million, signaling continued demand momentum and operating discipline. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001325618/000110465926024691/irmd-20251231x10k.htm))